CJC-1295 (No DAC) + GHRP-6 – 5mg / 5mg (3ml Pen)

CJC-1295 No DAC + GHRP-6 5mg/5mg – Growth Hormone Research Peptide Blend

CJC-1295 No DAC + GHRP-6 is a dual-peptide research formulation combining a growth hormone-releasing hormone (GHRH) analogue with a synthetic growth hormone secretagogue. Supplied in a 3ml pen containing 5mg of each compound, this combination is investigated for its effects on growth hormone secretion, pituitary signalling, appetite regulation and metabolic pathways associated with muscle physiology.

The formulation brings together two compounds that act through separate receptor systems. CJC-1295 No DAC stimulates GHRH receptors, while GHRP-6 activates ghrelin receptors, making the combination relevant to studies investigating interactions between hormonal signalling pathways.

CJC-1295 + GHRP-6 and Muscle Growth Research

Growth hormone is involved in several physiological processes associated with muscle tissue, protein metabolism, cellular development and energy regulation.

CJC-1295 No DAC and GHRP-6 are investigated for their ability to influence growth hormone secretion through complementary biological mechanisms. Research involving GHRH analogues and ghrelin receptor agonists has demonstrated that simultaneous receptor activation can produce a greater growth hormone response than stimulation through either pathway alone.

These mechanisms are of interest in research examining:

• Growth hormone secretion and endocrine regulation
• Muscle development and protein metabolism
• Pituitary hormone signalling
• Appetite regulation and metabolic responses
• Hormonal pathways associated with tissue growth
• Growth hormone secretagogue interactions

While growth hormone pathways are relevant to muscle physiology, evidence that this specific peptide combination directly improves muscle growth, recovery or athletic performance in humans remains insufficient.

Researchers investigating these mechanisms can explore our wider collection of peptides for muscle growth and performance, featuring compounds studied for their involvement in growth hormone activity, muscle physiology and performance-related biological processes.

Mechanism of Action

The CJC-1295 No DAC + GHRP-6 combination interacts with two separate regulatory pathways involved in growth hormone secretion.

CJC-1295 No DAC (GHRH Analogue)

CJC-1295 No DAC is a modified growth hormone-releasing hormone analogue designed to resist enzymatic degradation. It acts on pituitary GHRH receptors, activating intracellular cAMP signalling pathways involved in stimulating growth hormone secretion.

Unlike DAC-containing analogues, this version has a shorter duration of action and is investigated in research examining pulsatile growth hormone release.

GHRP-6 (Growth Hormone Secretagogue)

GHRP-6 is a synthetic peptide that activates the growth hormone secretagogue receptor GHS-R1a, commonly referred to as the ghrelin receptor.

Its activity influences growth hormone signalling through mechanisms distinct from GHRH receptor activation.

GHRP-6 is also associated with pronounced appetite signalling, making it relevant to research investigating hypothalamic feeding pathways, energy balance and endocrine responses.

Research Status and Scientific Findings

Growth Hormone Pathway Synergy

Research has demonstrated that simultaneous activation of GHRH and ghrelin receptors can produce synergistic growth hormone secretion. However, findings involving individual compounds should not automatically be treated as proof of efficacy for specific fixed-dose combinations.

Appetite and Metabolic Signalling

GHRP-6 has been investigated for its influence on appetite-related signalling pathways, particularly through ghrelin receptor activation and hypothalamic mechanisms involved in feeding behaviour.

Somatostatin Regulation

Research suggests that ghrelin receptor agonists can influence the inhibitory regulation of growth hormone secretion, including interactions involving somatostatin signalling.

Endocrine Selectivity

GHRP-6 may also

The combination engages two distinct pituitary signalling pathways. Research describes GHRH receptor agonism producing cAMP-mediated stimulation of somatotrophs, while ghrelin receptor (GHS-R1a) agonism acts through a separate pathway involving both direct somatotroph stimulation and suppression of somatostatin tone. Because the two receptors are independent and somatostatin functions as the principal brake on release, studies report that simultaneous engagement produces a response greater than the sum of the individual pathways. Selectivity characteristics differ between the available ghrelin receptor agonists.

Synergy between GHRH and ghrelin receptor pathways is one of the better-replicated findings in secretagogue pharmacology. Research on specific fixed combinations is considerably thinner than research on the underlying principle.

Pathway synergy

Well-replicated research showing greater release from simultaneous GHRH and GHS-R1a engagement.

Somatostatin tone

Studies on ghrelin receptor agonism reducing the principal inhibitory brake on secretion.

GHRP-6 appetite signalling

Pronounced hypothalamic feeding circuit activity documented in animal models.

Selectivity trade-off

Cortisol and prolactin elevation greater than that of the selective agonists.

Anti-doping context

Growth hormone secretagogues are listed by anti-doping authorities.